Long-term mortality in the United States cohort of pituitary-derived growth hormone recipients

Journal of Pediatrics

Volumn 144, Issue 4, 2004, Pages 430-436

  Mills, James L ^a   Schonberger, Lawrence B ^b   Wysowski, Diane K ^b   Brown, Paul ^b   Durako, Stephen J ^b   Cox, Christopher ^b   Kong, Fanhui ^b   Fradkin, Judith E ^b  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; RECOMBINANT GROWTH HORMONE;

ADRENAL INSUFFICIENCY; ARTICLE; CHILD; CREUTZFELDT JAKOB DISEASE; DEATH; FEMALE; GROWTH HORMONE DEFICIENCY; HIGH RISK PATIENT; HUMAN; HYPOGLYCEMIA; HYPOPHYSIS; HYPOPITUITARISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SIDE EFFECT; SUDDEN DEATH; UNITED STATES;

EID: 1842502935     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2003.12.036     Document Type: Article

References (14)

1. Mills JL, Fradkin J, Schonberger L, Gunn W, Thomson RA, Piper J, et al. Status report on the U.S. human growth hormone recipient follow-up study. Horm Res 1990;33:116-20.
2. Fradkin JE, Schonberger LB, Mills JL, Piper JM, Wysowski DK, Thomson R, et al. Creutzfeldt-Jakob disease in pituitary growth hormone recipients in the United States. JAMA 1991;265:880-4.
3. National Center for Health Statistics. Vital Statistics of the United States. Vol. II. Mortality. Part B. Washington, DC: Public Health Service; 1996.
4. Swerdlow AJ, Higgins CD, Adlard P, Preece MA. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study. Lancet 2002;360:273-7.
5. Kappy MS, Bajaj L. Recognition and treatment of endocrine/metabolic emergencies in children: part I. Adv Pediatr 2002;49:245-72.
6. Arlt W, Allolio B. Adrenal insufficiency. Lancet 2003;361:1881-93.
7. Taback SP, Dean HJ, Canadian Growth Hormone Advisory Committee. Mortality in Canadian children with growth hormone (GH) deficiency receiving GH therapy 1967-1992. J Clin Endocrinol Metab 1996;81:1693-6.
8. Buchanan CR, Preece MA, Milner RD. Mortality, neoplasia and Creutzfeldt-Jakob disease in patients treated with human pituitary growth hormone in the United Kingdom. BMJ 1991;302:824-8.
9. Goujard J, EntatM, Maillard F, Mugnier F, Rappaport R, Job JC. Human pituitary growth hormone (hGH) and Creutzfeldt-Jakob disease: results of an epidemiological survey in France, 1986. Int J Epidemiol 1988;17:423-7.
10. Hintz RL. Eternal vigilance-mortality in children with growth hormone deficiency. J Clin Endocrinol Metab 1996;81:1691-2.
11. Brown P, Gajdusek DC, Gibbs CJ Jr, Asher DM. Potential epidemic of Creutzfeldt-Jakob disease from human growth hormone therapy. N Engl J Med 1985;313:728-31.
12. Gibbs CJ Jr. Creutzfeldt-Jakob disease and related transmissible spongiform encephalopathies. N Engl J Med 1998;339:1994-2004.
13. Vance ML, Mauras N. Growth hormone therapy in adults and children. N Engl J Med 1999;341:1206-16.
14. Brown P, Preece M, Brandel J-P, Sato T, McShane L, Zerr I, et al. Iatrogenic Creutzfeldt-Jakob disease at the millennium. Neurology 2000;55:1075-81.